The apoptosis-inducing effect of CD133-PCAD-DMSN@DOX was investigated using flow cytometry, which demonstrated that Apt-PCAD-DMSN@DOX led to a higher reduction in the population of CD133-positive cancer cells (48%) than the nontargeted formulation (36%) [53]. This evidence concerns the gene PROM1 and cancer.